



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682
		Filing Date	January 23, 2001
		First Named Inventor	Morris Reichlin
		Group Art Unit	
		Examiner Name	
Sheet 1 of 8	Attorney Docket Number	OMRF 158 CIP CON	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
1035		4,602,003		Malinow	07-22-1986	- -
		4,944,944		Tang, et al.	07-31-1990	- -
		4,976,968		Steiner	12-11-1990	- -
		5,017,565		Lange III, et al.	05-21-1991	- -
		5,063,210		Lange, III, et al.	11-05-1991	- -
		5,173,408		Lange, III, et al.	12-22-1992	- -
		5,200,183		Tang, et al.	04-06-1993	- -
		5,376,640		Miyazaki, et al.	12-27-1994	- -
		5,519,001		Kushwaha, et al.	05-21-1990	- -
		RE 33,885		Mattson	04-14-1992	- -

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office. ³	Number ⁴	Kind Code ⁵ (if known)			
1035		EP	0 333 523	A2	The UAB Research Foundation	09-20-1989	
		WO	89/08465	A1	Teruno Kabushiki Kaisha	09-21-1989	
		WO	91/06286	A1	Enzytech, Inc.	05-16-1991	
		WO	91/06287	A1	Enzytech, Inc.	05-16-1991	
		WO	94/20610	A1	Aktiebolaget Astra	09-15-1994	

Examine Signature		Date Considered	3/20/2003
-------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Continuation of 08/800,682	
				Filing Date	
				January 23, 2001	
				First Named Inventor	
		Morris Reichlin			
Group Art Unit					
Examiner Name					
Sheet	2	of	8	Attorney Docket Number	
				OMRF 158 CIP CON	

 Jc882 U.S. PTO
 09/768155
 10/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
		AARDEN, et al., "Immunology Of DNA. III. Crithidia Luciliae, A Simple Substrate For The Determination Of Anti-dsDNA With The Immunofluorescence Technique," <i>Ann. NY Acad. Sci.</i> 254:505-515 (1975).
		ALTSCHUL, et al., "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> 215:403-410 (1990).
		ANDRE-SCHWARTZ, et al., "Binding Of Cytoskeletal Proteins By Monoclonal Anti-DNA Lupus Autoanti-Bodies," <i>Clin. Immunol. Immunopathol.</i> 31:261 (1984).
		BARADA, et al., "Antibodies To Sm In Patients With Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 24:1236-1244 (1981).
		BEAULIEU, et al., "IgG Antibodies To Double-Stranded DNA In Systemic Lupus Erythematosus Sera," <i>Arthritis Rheum.</i> 22:565-570 (1979).
		BLOOM, et al., "Overlap Of The Anti-Sm And Anti-DNA Responses Of MRL/Mp-lpr/lpr Mice," <i>J. Immunol.</i> 150:1579 (1993).
		BOREL & BOREL, "Oligonucleotide Linked To Human Gammaglobulin Specifically Diminishes Anti-DNA Antibody Formation In Cultured Lymphoid Cells From Patients With Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 82:1901-1907 (1988).
		BOREL, et al., "Prevention Of Murine Lupus Nephritis By Carrier-Dependent Induction Of Immunologic Tolerance To Denatured DNA," <i>Science</i> 182:76-77 (1973).
	BOREL, et al., "Treatment Of Lupus Nephritis In Adult (NZB + NZW)F Mice By Cortisone-Facilitated Tolerance To Nucleic Acid Antigens," <i>J. Clin. Invest.</i> 61:276-286 (1978).	
	CLACKSON, et al., "Making Antibody Fragments Using Phage Display Libraries," <i>Nature</i> 352:624-688 (1991).	

Examiner's Signature		Date Considered	3/20/2003
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	
				Continuation of 08/800,682	
				Filing Date	
				January 23, 2001	
				First Named Inventor	
		Morris Reichlin			
Group Art Unit					
Examiner Name					
Sheet	3	of	8	Attorney Docket Number	
				OMRF 158 CIP CON	

 PTO
 09/16/01
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MB		CLARK, et al., "Characterization Of A Soluble Cytoplasmic Antigen Reactive With Sera From Patients With Systemic Erythematosis," <i>J. Immunol.</i> 102(1):117-122 (1969).	
		DALE, et al., "A Rapid Single-Stranded Cloning Strategy For Producing A Sequential Series Of Overlapping Clones For Use In DNA Sequencing: Application To Sequencing The Corn Mitochondrial 18S rDNA," <i>Plasmid</i> 13:31-40 (1985).	
		DAUGHERTY, et al., "Polymerase Chain Reaction Facilitates The Cloning, CDR-Grafting, And Rapid Expression Of A Murine Monoclonal Antibody Directed Against The CD18 Component Of Leukocyte Integrins," <i>Nucl. Acids Res.</i> 19:2471-2476 (1991).	
		DEVEREUX, et al., "A Comprehensive Set Of Sequence Analysis Programs For The VAX," <i>Nucleic Acids Res.</i> 12:387-395 (1984).	
		DIVALERIO, et al., "Anti-DNA Antibodies Can React Specifically With DNA In The Context Of Glomeruli," <i>Clin. Res.</i> 42:139A (1994).	
		EKLUND, et al., "Cloning Of A cDNA Encoding A Human DNA-Binding Protein Similar To Ribosomal Protein S1," <i>Gene</i> 155:231-235 (1995).	
		FRANZETTI, et al., "Characterization And RNA-Binding Properties Of A Chloroplast S1-Like Ribosomal Protein," <i>J. Biol. Chem.</i> 267:19075-19081 (1992).	
		FRIGUET, et al., "Measurement Of The True Affinity Constant In Solution Of Antigen-Antibody Complexes By Enzyme-Linked Immunosorbent Assay," <i>J. Immunol. Methods</i> 77:305 (1985).	
		GISH & STATES, "Identification Of Protein Coding Regions By Database Similarity Search," <i>Nature Genetics</i> 3:266-271 (1993).	
	GONZALEZ & ROTHFIELD, "Immunoglobulin Class And Pattern Of Nuclear Fluorescence In Systemic Lupus Erythematosis," <i>N. Engl. J. Med.</i> 274:1333-1338 (1966).		

Examiner's Signature		Date Considered	3/20/2003
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682
		Filing Date	January 23, 2001
		First Named Inventor	Morris Reichlin
		Group Art Unit	
		Examiner Name	
Sheet 4 of 8	Attorney Docket Number	OMRF 158 CIP CON	

 PTO
 08/800,682
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
B35		HAHN & TSAO, "Antibodies To DNA: In Dubois, Systemic Lupus Erythematosus, Wallace & Hahn, Eds. Lea & Febiger, Philadelphia, PA, 195-201 (1993).	
		HAMILTON, et al., "Two Ro (SS-A) Autoantibody Responses In Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 31:496-505 (1988).	
		HANDWERGER, et al., "Palmerston North Mice Produce Antibodies To U1RNP And SM Particles," <i>Clin. Res.</i> 42:315A (1994).	
		HARLEY, et al., "A Model For Disease Heterogeneity In Systemic Lupus Erythematosus: Relationship Between Histo-Compatibility Antigens, Autoantibodies, And Lymphopenia, Or Renal Disease," <i>Arthritis Rheum.</i> 32(7):826-836 (1989).	
		ITOH, et al., "Heterogeneity Of The Ro/SSA Antigen And Autoanti-Ro/SSA Response: Evidence Of The Four Antigenically Distinct Forms," <i>Clin. Exp. Immunol.</i> 81:45-51 (1990).	
		JACO, et al., "Human Systemic Lupus Erythematosus Sera Contain Antibodies Against Cell Surface Protein(s) That Share(s) Epitope(s) With DNA," <i>Proc. Natl. Acad. Sci. USA</i> 83:6970 (1986).	
		JAENISCH, "Transgenic Animals" <i>Science</i> 240:1468-1474 (1988).	
		KABAT, et al., "Sequences Of Proteins Of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD (1987).	
		KASUKAWA & SHARP, Ed. (Excerpta Medica, Elsevier Science Pub., Amsterdam, 85-96 <u>Mixed Connective Tissue Disease And Anti-Nuclear Antibodies</u> (1987).	
		KOFFLER, et al., "Antibodies To Polynucleotides In Human Sera: Antigenic Specificity And Relation To Disease," <i>J. Exp. Med.</i> 134:294-312 (1971).	

Examiner's Signature		Date Considered	3/20/2002
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682		
		Filing Date	January 23, 2001		
		First Named Inventor	Morris Reichlin		
		Group Art Unit			
		Examiner Name			
Sheet	5	of	8	Attorney Docket Number	OMRF 158 CIP CON

 1-882 U.S. PTO
 09/768155
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
m		KOREN, et al., "Murine and Human Antibodies to Native DNA that Cross-React with the A and D SnRNP Polypeptides Cause Direct Injury of Cultured Kidney Cells," <i>J. Immunol.</i> 154(9):4857-4864 (1995).	
		LEONING, "The Fractionation of High-Molecular-Weight Ribonucleic Acid by polyacrylamide-Gel Electrophoresis," <i>Biochem. J.</i> 102:251 (1967).	
		MADDISON & REICHLIN, "Deposition Of Antibodies To A Soluble Cytoplasmic Antigen In The Kidneys Of Patients With Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 22:858-863 (1979).	
		MADDISON, et al., "Patterns Of Clinical Disease Associated With Antibodies To Nuclear Ribonucleoprotein," <i>J. Rheumatol.</i> 5:407-411 (1978).	
		MATTER, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <i>Arthritis Rheum</i> 25:1278 (1982).	
		MATTIOLI, et al., "Characterization Of A Soluble Nuclear Ribonucleoprotein Antigen Reactive With Sle Sera," <i>J. Immunol.</i> 107(5):1281-1290 (1971).	
		MATTIOLI, et al., "Heterogeneity Of RNA Protein Antigens Reactive With Sera Of Patients With Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 17:421-429 (1974).	
		MINITER, et al., "Reassessment Of The Clinical Significance Of Native DNA Antibodies In Systemic Lupus Erythematosus," <i>Arthritis Rheum.</i> 22(9):959-968 (1979).	
		PENNEBAKER, "Immunoglobulin Classes of DNA Binding Activity in Serum and Skin in Systemic Lupus Erythematosus," <i>Journal of Clinical Investigation</i> 60:1331-1338 (1977).	
		PISETSKY, et al., "Specificity And Idiotypic Analysis Of A Monoclonal Anti-Sm Antibody With Anti-DNA Activity," <i>J. Immunol.</i> 135:4080 (1985).	

Examiner's Signature		Date Considered	3/20/2003
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682
		Filing Date	January 23, 2001
		First Named Inventor	Morris Reichlin
		Group Art Unit	
		Examiner Name	
Sheet 6 of 8	Attorney Docket Number	OMRF 158 CIP CON	

 JCS882 U.S. PTO
 09/768155
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
B3		POORMAN, et al., "Isolation and Characterization of Native Human Renin Derived From Chinese Hamster Ovary Cells," <i>Proteins: Structure, Function and Genetics</i> 1(2):139-145 (1986).	
		PROVOST, et al., "Lupus Band Test in Untreated SLE Patients: Correlation of Immunoglobulin Deposition in the Skin of the Extensor Forearm with Clinical Renal Disease and Serological Abnormalities," <i>Journal of Investigative Dermatology</i> 74(6):407-412 (1980).	
		RADIC, et al., "Residues That Mediate DNA Binding Of Autoimmune Antibodies," <i>J. Immunol.</i> 150:4966 (1993).	
		RAZ, et al., "Anti-DNA Antibodies Bind Director To Renal Antigens And Induce Kidney Dysfunction In The Isolated Perfused Rat Kidney," <i>J. Immunol.</i> 142:3076 (1989).	
		RAZ, et al., "Cross-reactions of anti-DNA autoantibodies with cell surface proteins," <i>Eur. J. Immunol.</i> 23:383-390 (1993).	
		REICHLIN & MATTIOLI, "Correlation Of A Precipitin Reaction To An Rnprotein Antigen And A Low Prevalence Of Nephritis In Patients With Systemic Lupus Erythematosus," <i>N. Engl. J. Med.</i> 286:908-911 (1972).	
		REICHLIN, et al., "Characterization of Anti-dsDNA Antibodies: Cross Reaction with SnRNP Polypeptides and Cell-Binding Abilities," <i>The Immunologist</i> 3/3 84-88 (1995).	
		REICHLIN, et al., "Lupus Autoantibodies To Native DNA Cross-React With The A And D SnRNP Polypeptides," <i>J. Clin. Invest.</i> 93:443-449 (1994).	
		SANGER, et al., "DNA Sequencing With Chain Terminating Inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> 74:5463-5467 (1977).	
✓		SCHNIER & FAIST, "Comparison Studies On The Structural Gene For The Ribosomal Protein S1 In Ten Bacterial Species," <i>Mol. Gen. Genet.</i> 200:476-481 (1985).	

Examiner's Signature		Date Considered	7/20/2001
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682
		Filing Date	January 23, 2001
		First Named Inventor	Morris Reichlin
		Group Art Unit	
		Examiner Name	
Sheet	7	of	8
		Attorney Docket Number	OMRF 158 CIP CON

 JCS82 U.S. PTO
 09/768155
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MS		SCHNIER, et al., "Cloning And Characterization Of A Gene From Rhizobium Melilotii 2011 Coding For Ribosomal Protein S1," <i>Nucleic Acids Res.</i> 16:3075-3089 (1998).	
		SCHUR & SANDSON, "Immunological Factors And Clinical Activity In Systemic Lupus Erythematosus," <i>N. Engl. J. Med.</i> 278:533-538 (1982).	
		SHARP, et al., "Mixed Connective Tissue Disease-An Apparently Distinct Rheumatic Disease Syndrome Associated With A Specific Antibody To An Extractable Nuclear Antigen (ENA)," <i>Am. J. Med.</i> 52:148-159 (1972).	
		SMITH & JOHNSON, "Single-step Purification Of Polypeptides Expressed In Escherichia Coli As Fusions With Glutathione S-transferase," <i>Gene (Amst.)</i> , 67:31 (1988).	
		SUBRAMANIAN, "Structure And Functions Of Ribosomal Protein S1," <i>Prog. Nucleic Acids Res. Mol. Biol.</i> 28:101-142 (1983).	
		TALAL, et al., "Immunologic Regulation of Spontaneous Antibodies to DNA and RNA; I. Significant of IgM and IgG Antibodies in SLE Patients and Asymptomatic Relatives," <i>Clin. exp. Immunol.</i> 25:377-382 (1976).	
		TAN & KUNKEL, "Characteristics Of A Soluble Nuclear Antigen Precipitating With Sera Of Patients With Systemic Lupus Erythematosus," <i>J. Immunol.</i> 99(3):464-471 (1996).	
		TAN, et al., "Deoxyribonucleic Acid (DNA) And Antibodies To DNA In The Serum Of Patients With Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 45:1732-1740 (1966).	
	TARGOFF, et al., "Anti-KJ: A New Antibody Associated with the Syndrome of Polymyositis and Interstitial Lung Disease," <i>J. Clin. Invest.</i> 84:162.		
	TSO, et al., "Structural Characteristics Of The Variable Regions Of Immunoglobulin Genes Encoding A Pathogenic Autoantibody In Murine Lupus," <i>J. Clin. Invest.</i> 85:530-540 (1990).		

Examiner's Signature		Date Considered	3/20/2001
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 08/800,682		
		Filing Date	January 23, 2001		
		First Named Inventor	Morris Reichlin		
		Group Art Unit			
		Examiner Name			
Sheet	8	of	8	Attorney Docket Number	OMRF 158 CIP CON

 JCSB U.S. PTO
 08/768155
 01/23/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
ms		TSUZAKA, et al., "Lupus Autoantibodies to Double-Stranded DNA Cross-React with Ribosomal Protein S1," <i>Journal of Immunology</i> 156:1668-1675 (1996).	
		VLACHAKOS, et al., "Murine Monoclonal Anti-DNA Antibodies Penetrate Cells, Bind To Nuclei, And Induce Glomerular Proliferation And Proteinuria In Vivo ^{1,2} ," <i>J. Am. Soc. Nephrol.</i> 2:1345-1354 (1992).	
		WASICEK & REICHLIN, "Clinical And Serological Differences Between Systemic Lupus Erythematosus Patients With Antibodies To Ro Versus Patients With Antibodies To Ro And La," <i>J. Clin. Invest.</i> 69:835-843 (1982).	
		WINFIELD, et al., "Specific Concentration Of Polynucleotide Immune Complexes In The Cryoprecipitates Of Patients With Systemic Lupus Erythematosus," <i>J. Clin. Invest.</i> 56:563-570 (1975).	
		WINKLER, et al., "IgG Human Monoclonal Anti-DNA Autoantibodies From Patients With Systemic Lupus Erythematosus," <i>Clin. Exp. Immunol.</i> 85:379-385 (1991).	
		YANASE, et al., "A Subgroup Of Murine Monoclonal Anti-Deoxyribonucleic Acid Antibodies Of Murine Monoclonal Anti-Deoxyribonucleic Acid Antibodies Traverse The Cytoplasm And Enter The Nucleus In A Time-And Temperature-Dependent Manner," <i>Lab. Invest.</i> 71:52-60 (1994).	
		YOUNG & DAVIS, "Efficient Isolation Of Genes By Using Antibody Probes", <i>Proc. Natl. Acad. Sci. USA</i> 80:1194-1198 (1983).	
		ZACK, et al., "DNA Mimics A Self-Protein That May Be A Target For Some Anti-DNA Antibodies In Systemic Lupus Erythematosus," <i>J. Immunol.</i> 154:1987 (1995).	
✓		HAHN & EBLING, "Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA," <i>J Immunol</i> 132(1):187-90 (1984).	
		SASAKI, et. al., "Selective elimination of anti-DNA antibody-producing cells by antiidiotypic antibody conjugated with neocarzinostatin," <i>J Clin Invest</i> 77(4):1382-6 (1986).	

Examiner's Signature		Date Considered	7/20/2001
----------------------	--	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.